VANCOUVER, British Columbia, May 29, 2025 (GLOBE NEWSWIRE) -- Coppernico Metals Inc. (TSX: COPR, OTCQB: CPPMF) (“Coppernico” or the “Company”), is pleased to announce the details of its upcoming virtual Annual General Meeting of Shareholders (the "Meeting"), to be held on Tuesday, June 24, 2025, at 10:00 a.m. Pacific Time, as well as a leadership fireside chat hosted by 3L Capital (the "Webinar"), scheduled for Wednesday, June 4, 2025, at 8:00 a.m. Pacific Time. Annual General Meeting of Shareholders The Me ...

WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced management’s presentation at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 1:25 p.m. ET. A live webcast and archived replay of the Company’s presentation can be accessed under “Events and Presentati ...

~ No serious adverse events and 92% reduction in seizure frequency observed in the first trial participant through first five months of follow up ~ ~ Data to be presented today at Epilepsy Therapies & Diagnostics Development Symposium (ETDD) ~ LEXINGTON, Mass. and AMSTERDAM, May 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the presentation of a clinical case study of the fir ...

Core Viewpoint - Immunic, Inc. has announced a public offering of pre-funded warrants and series A and B warrants, aiming to raise approximately $65 million initially, with potential total gross proceeds of up to $130 million if all warrants are exercised [1][3]. Group 1: Offering Details - The public offering price for one Pre-Funded Warrant, one Series A Warrant, and one Series B Warrant is set at $0.7499 [1]. - The Pre-Funded Warrants are immediately exercisable, while Series A Warrants can be exercised until December 31, 2025, and Series B Warrants can be exercised starting October 1, 2025, for a period of five years [1]. - The offering is expected to close around June 3, 2025, pending customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to fund clinical trials, operations, and other general corporate purposes [4]. Group 3: Company Overview - Immunic, Inc. is focused on developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases, with its lead program, vidofludimus calcium (IMU-838), currently in phase 3 trials for relapsing multiple sclerosis [7]. - Vidofludimus calcium has shown therapeutic activity in earlier trials and combines neuroprotective effects with anti-inflammatory properties [7]. - The company is also developing IMU-856 for gastrointestinal diseases and IMU-381, which is in preclinical testing [7].

TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- Xtract One Technologies Inc. (TSX: XTRA) (OTCQX: XTRAF) (FRA: 0PL) (“Xtract One” or the “Company”), a leading technology-driven threat detection and security solution that prioritizes the patron access experience by leveraging AI, today announced that it will release fiscal 2025 third quarter results after the close of trading on June 5, 2025. Peter Evans, Xtract One CEO and Director, and Karen Hersh, CFO and Corporate Secretary, will host a webcast and conference c ...

HOUSTON, May 29, 2025 (GLOBE NEWSWIRE) -- Whitestone REIT (NYSE: WSR) (“Whitestone” or the “Company”) today announced that CEO Dave Holeman will participate in a “Fireside Chat” at Nareit’s 2025 REITweek Investor Conference. Mr. Holeman will be hosted by Truist Analyst Anthony Hau. When: Tuesday, June 3, 2025 at 9:30 EasternLink to Audio: https://ir.whitestonereit.com/corporate-profile/default.aspx About Whitestone REIT Whitestone REIT (NYSE: WSR) is a community-centered real estate investment trust (REIT) ...

Hong Kong, May 29, 2025 (GLOBE NEWSWIRE) -- Top Win International Limited (the “Company”) today announced transformative initiatives to reinforce its leadership in Asia’s fast-growing digital assets sector. Building on its strategic pivot to the Web3 ecosystem, the Company is making strategic investments in two key Asia-listed companies and has effected a ticker change to align with its forward-looking digital assets vision. Strategic Investments in Asia’s Digital Assets Leaders The Company is deepening it ...

Group 1 - Tilray Brands, Inc. will participate in the TD Cowen 9th Annual Future of the Consumer Conference on June 3, 2025, in New York, with a fireside chat scheduled for 11:00 a.m. ET [1] - The company is recognized as a global leader in the lifestyle and consumer packaged goods sector, focusing on cannabis, beverage, wellness, and entertainment industries [3] - Tilray operates in multiple regions including Canada, the United States, Europe, Australia, and Latin America, supporting over 40 brands in more than 20 countries [3]

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference with a fireside chat on Thursday, June 5, 2025, at 1:25 p.m. ET.Goldman Sachs 46th Annual Global Healthcare Conferen ...

REDWOOD CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced the launch of its new Proteograph® Product Suite, featuring the Proteograph ONE Assay and SP200 Automation Instrument—its most advanced solution yet for scalable, high-resolution, mass spec-based proteomics. Seer’s newest innovation, debuting at the upcoming American Society for Mass Spectrometry (ASMS) annual conference in Baltimore, MD, ov ...